The Latest

  • An illustrated image of clinical development for a BioPharma Dive 2021 outlook story
    Image attribution tooltip
    Kendall Davis/BioPharma Dive
    Image attribution tooltip
    Tracker

    10 clinical trials to watch in the first half of 2026

    After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and many rare conditions could help it continue.

  • Equipments in a pharmaceutical factory
    Image attribution tooltip
    Permission granted by ESS Technologies, a Pacteon Company
    Image attribution tooltip
    Sponsored by Pacteon Group

    Why US-manufactured pharmaceutical packaging equipment matters

    As manufacturers modernize operations, the origin of their equipment is a strategic consideration.

  • An illustration of stock market quotes.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    RallyBio tries again for reverse merger, this time with Avenzo

    It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.

  • A micrograph of a myeloma neoplasm in a bone marrow biopsy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Bristol Myers unveils data for one of its next-gen blood cancer drugs

    Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.

  • Banners marking the 2025 American Society of Clinical Oncology's annual meeting hang from the ceiling of a conference hall.
    Image attribution tooltip
    Ned Pagliarulo/BioPharma Dive
    Image attribution tooltip

    ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting

    Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, BioNTech, Eli Lilly and Moderna.

  • A sign for the FDA is displayed outside the agency's headquarters in Silver Spring, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks

    A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.

  • FDA chaos
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    Can a chaotic FDA still deliver on faster drug development?

    As leadership changes create more instability at the FDA, here’s what one former agency official thinks it will take to keep speedier drug approvals on track.

    FDA
  • A "Pzifer" sign is mounted to a white-bricked building wall; behind the wall is the infrastructure of an industrial plant.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    China competition

    Pfizer, Innovent strike $10B cancer drug deal

    Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    AstraZeneca, Pfizer and Bristol Myers Squibb have each allocated more than $16 billion to collaborations with Chinese drugmakers since the start of 2025 — surpassing all of their pharmaceutical peers over that timeframe.

    Updated 21 hours ago
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Allogene CEO to step down; Agios drug fails key test

    David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.

  • A 3D illustration of the hepatitis B virus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

    The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

  • A pill bottle for Eli Lilly's oral weight loss medication Foundayo
    Image attribution tooltip
    Courtesy of Eli Lilly
    Image attribution tooltip
    Obesity drugs

    CVS obesity drug deal puts Lilly on equal footing with Novo

    The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. 

  • A horizontal headshot of Simeon George, CEO of SR One.
    Image attribution tooltip
    Permission granted by SR One
    Image attribution tooltip
    Q&A // China competition

    SR One’s Simeon George on how China is rewriting biotech’s venture playbook

    The veteran investor says that the trove of ready-made prospects is making the global biotech ecosystem “more competitive” and steering dollars away from “half-baked ideas.”

  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Kailera’s three-pronged obesity shot shows promise in early trial

    As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    RA Capital Management is investing $30 million in Secretome Therapeutics, a company developing a new kind of cell therapy for the heart muscle weakness associated with Duchenne muscular dystrophy.

    Updated May 28, 2026
  • A woman smiles at the camera.
    Image attribution tooltip
    Permission granted by Verge Genomics
    Image attribution tooltip
    Emerging biotech

    Verge, following trial failure, rebrands its AI drug discovery ambitions

    Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to patients who best benefit from them.

  • Close up of Wall Street sign, with tall buildings in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Cardio drugmaker Kardigan plans to go public

    Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.

  • An Eli Lilly logo is seen at the top of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    Lilly dives into vaccine research with 3 biotech buyouts

    Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

  • single science glass flask with double exposure scientist holding tube in chemistry blue laboratory with stock market information background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Apogee eczema drugs gets Blackstone backing, heads to Phase 3

    The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA delays decision on AstraZeneca breast cancer pill

    The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive in what would be a new kind of treatment setting.

    FDA
  • The headquarters of Eli Lilly & Co. is pictured on Aug. 1, 2019, in Indianapolis, Indiana.
    Image attribution tooltip
    "Eli Lilly Corporate Center, Indianapolis, Indiana, USA" by Momoneymoproblemz is licensed under CC BY-SA 4.0
    Image attribution tooltip
    Gene editing

    Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

    The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine

    The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.

  • A Bristol Myers Squibb employee works in one of the company's labs.
    Image attribution tooltip
    Permission granted by Bristol Myers Squibb
    Image attribution tooltip
    Q&A // Brain drug revival

    In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

    Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Kardigan, a startup run by former MyoKardia executives, outlined an offering that would support development of heart drugs licensed from Bristol Myers, Sanofi and Ionis Pharmaceuticals.

    Updated May 27, 2026
  • A sign with Eli Lilly's logo sits outside of the company's headquarters on March 17, 2024 in Indianapolis.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly’s triple-acting obesity drug hits goal in Phase 3 trial

    Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.

  • Brain pipette
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Parkinson’s drug from Biogen, Denali comes up short

    High-level results have led the companies to scrap a mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.

    Updated May 22, 2026